UK TimesUK Times
  • Home
  • News
  • TV & Showbiz
  • Money
  • Health
  • Science
  • Sports
  • Travel
  • More
    • Web Stories
    • Trending
    • Press Release
What's Hot
Faster and fairer justice for victims thanks to major magistrate recruitment drive

Faster and fairer justice for victims thanks to major magistrate recruitment drive

16 April 2026

Nine universities start legal action over student loan error row | UK News

16 April 2026
Influential evangelical Rev Franklin Graham dismisses controversy over Trump’s AI Jesus post as ‘a lot to do about nothing’ – UK Times

Influential evangelical Rev Franklin Graham dismisses controversy over Trump’s AI Jesus post as ‘a lot to do about nothing’ – UK Times

16 April 2026
Facebook X (Twitter) Instagram
Facebook X (Twitter) Instagram
UK TimesUK Times
Subscribe
  • Home
  • News
  • TV & Showbiz
  • Money
  • Health
  • Science
  • Sports
  • Travel
  • More
    • Web Stories
    • Trending
    • Press Release
UK TimesUK Times
Home » Anxiety drug Xanax is under recall. Here’s what to know – UK Times
News

Anxiety drug Xanax is under recall. Here’s what to know – UK Times

By uk-times.com15 April 2026No Comments2 Mins Read
Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
Anxiety drug Xanax is under recall. Here’s what to know – UK Times
Share
Facebook Twitter LinkedIn Pinterest Email

Sign up for our free Health Check email to receive exclusive analysis on the week in health

Get our free Health Check email

Get our free Health Check email

Health Check

Xanax, a drug used to treat anxiety disorders, has been placed under a nationwide recall.

Viatris, the maker of Xanax, recalled the medication last month because of “failed dissolution specifications.”

This means the pill may not break down in the body and release the drug at the right speed. If the medication doesn’t dissolve correctly, it could reduce its effectiveness.

Viatris did not issue a press release for the recall, according to the Food and Drug Administration’s recent notice, but it did send out notification letters.

Xanax, a drug used to treat anxiety disorders, has been placed under a nationwide recall
Xanax, a drug used to treat anxiety disorders, has been placed under a nationwide recall (AFP via Getty Images)

Last week, the FDA classified the recall as Class II, meaning the affected pills could cause “temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,” according to the agency.

The Independent has reached out to Viatris for comment.

Here are some additional details about the recall:

  • Product description: Xanax XR, alprazolam, extended-release tablets, 3 mg, 60 Tablets bottles, Rx only
  • Lot number: 8177156
  • Expiration date: February 28, 2027

Xanax is a benzodiazepine medicine. Benzodiazepines are depressants that slow down the body’s central nervous system, according to the Drug Enforcement Administration. They are used to treat anxiety, but can also be used to relieve muscle spasms and reduce seizures, the DEA says.

The Xanax website warns against taking the drug more than prescribed or sharing it with other people.

Consumers should also check their medicine cabinets for cough drops that were recently recalled
Consumers should also check their medicine cabinets for cough drops that were recently recalled (Getty Images)

Patients who take Xanax can reach Viatris customer relations at (800) 796-9526 or [email protected].

Consumers should also check their medicine cabinets for cough drops that were recently recalled.

Last month, China-based Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalled 15 cough drop products sold across the U.S. The recall was classified as Class II last week.

The cough drops were recalled following an FDA recommendation based on “certain observations” during an inspection of the manufacturing facility last August that “may bear on product quality,” according to an agency notice about the recall.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

Related News

Nine universities start legal action over student loan error row | UK News

16 April 2026
Influential evangelical Rev Franklin Graham dismisses controversy over Trump’s AI Jesus post as ‘a lot to do about nothing’ – UK Times

Influential evangelical Rev Franklin Graham dismisses controversy over Trump’s AI Jesus post as ‘a lot to do about nothing’ – UK Times

16 April 2026

M1 southbound between J25 and J24A | Southbound | AuthorityOperation

16 April 2026

M1 J11A southbound exit | Southbound | Road Works

16 April 2026

Why some argue cutting costs is the best way to cut carbon | UK News

16 April 2026
Government urged to act on ultra-processed food adverts over child health fears – UK Times

Government urged to act on ultra-processed food adverts over child health fears – UK Times

16 April 2026
Top News
Faster and fairer justice for victims thanks to major magistrate recruitment drive

Faster and fairer justice for victims thanks to major magistrate recruitment drive

16 April 2026

Nine universities start legal action over student loan error row | UK News

16 April 2026
Influential evangelical Rev Franklin Graham dismisses controversy over Trump’s AI Jesus post as ‘a lot to do about nothing’ – UK Times

Influential evangelical Rev Franklin Graham dismisses controversy over Trump’s AI Jesus post as ‘a lot to do about nothing’ – UK Times

16 April 2026

Subscribe to Updates

Get the latest UK news and updates directly to your inbox.

Recent Posts

  • Faster and fairer justice for victims thanks to major magistrate recruitment drive
  • Nine universities start legal action over student loan error row | UK News
  • Influential evangelical Rev Franklin Graham dismisses controversy over Trump’s AI Jesus post as ‘a lot to do about nothing’ – UK Times
  • M1 southbound between J25 and J24A | Southbound | AuthorityOperation
  • M1 J11A southbound exit | Southbound | Road Works

Recent Comments

No comments to show.
© 2026 UK Times. All Rights Reserved.
  • Privacy Policy
  • Terms of use
  • Advertise
  • Contact Us

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version